mannitol has been researched along with g(m3) ganglioside in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alonso, D; Anasagasti, L; Arango, Mdel C; Carr, A; Fernández, LE; Gómez, E; González, J; González, JL; Gracia, E; Joan, A; Melgares, Mde L; Noris, E; Osorio, M; Pérez, R; Rengifo, E; Rodríguez, E; Saurez, G; Torres, I; Torriella, A | 1 |
| Crombet, T; Curbelo, I; Estevez, A; Fernandez, LE; Gonzalez, Z; Lorenzo-Luaces, P; Mazorra, Z; Mulens, V; Perez, K; Rubio, MC; Valdes-Zayas, A; Vega, AM | 1 |
2 trial(s) available for mannitol and g(m3) ganglioside
| Article | Year |
|---|---|
Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study.
Topics: Adult; Aged; Bacterial Outer Membrane Proteins; Cancer Vaccines; Eye Neoplasms; Female; G(M3) Ganglioside; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Liposomes; Male; Mannitol; Melanoma; Middle Aged; Neisseria meningitidis; Oleic Acids; Skin Diseases; Survival Analysis; Treatment Outcome; Vaccination; Vitiligo | 2008 |
Immunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy.
Topics: Adjuvants, Immunologic; Antibodies; Apoptosis; Bacterial Outer Membrane Proteins; Biomarkers, Pharmacological; Breast Neoplasms; Cancer Vaccines; Cell Line, Tumor; Female; G(M3) Ganglioside; Humans; Immunity, Humoral; Mannitol; Middle Aged; Neisseria meningitidis; Neoplasm Staging; Oleic Acids; Treatment Outcome | 2017 |